Maqola mavzusi

Mualliflar

Nabieva F.S., Xaribova E.A.

Muassasa

Buxoro davlat tibbiyot instituti

Annotatsiya

Dunyo bo'ylab ayollar bachadon bo'yni saratoni bilan bog'liq jiddiy sog'liq muammosiga duch kelishmoqda. Aholi skrining dasturlari, emlash kampaniyalari, patogenez jarayon-larini batafsil o'rganish va bemorlarni tashxislash va davolash strategiyalarini ishlab chiqishga qaramay, kasallanishlar soni yil sayin ortib bormoqda. Kasallikning rivojlanishi, ayniqsa bachadon bo'yni saratonining takroriy holatlarida sezilarli bo'ladi. Bachadon bo'yni saratoni holatlarining 10 dan 40 foizigacha kimyoterapiya va kombinatsiyalangan nur terapiyasidan keyin takrorlanadi.

Kalit so'zlar

bachadon bo'yni saratoni, inson papillomavirusi (HPV), suyuq biopsiya, raqamli tomchi polimeraza zanjiri reaktsiyasi, aylanma o'simta DNKsi

Adabiyotlar

1. Zhang S., Xu H., Zhang L., Qiao Y. Cervical cancer: epidemiology, risk factors and screening. Chin J Cancer Res 2020;32(6):720– 28. DOI: 10.21147/j.issn.1000-9604.2020.06.05
2. Choi S., Ismail A., Pappas-Gogos G., Boussios S. HPV and cervical cancer: a review of epidemiology and screening uptake in the UK. Pathogens 2023;12:298. DOI: 10.3390/pathogens12020298
3. Nygård M., Nygård S. The future of cervical cancer prevention: from “one-size-fitsall” to personalized screening. J Pers Med 2023;13:161. DOI: 10.3390/jpm13020161
4. Gopu P., Antony F., Cyriac S. et al. Updates on systemic therapy for cervical cancer. Ind J Med Res 2021;154(2):293–302. DOI: 10.4103/ijmr.IJMR_4454_20
5. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6): 394–424. DOI: 10.3322/caac.21492
6. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660
7. Arbyn M., Weiderpass E., Bruni L. et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020;8(2):191–203. DOI: 10.1016/s2214-109X(19)30482-6
8. Fowler J.R., Maani E.V., Dunton C.J., Jack B.W. Cervical Cancer. 2022. Treasure Island: StatPearls Publishing, 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK43109 3/.
9. Singh D., Vignat J., Lorenzoni V. et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health 2023;11(2):197–206. DOI: 10.1016/S2214-109X(22)00501-0
10. Ferlay J., Ervik M., Lam F. et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. Available at: https://gco.iarc.fr/today.
11. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7–34. DOI: 10.3322/caac.21551
12. Shrestha A.D., Neupane D., Vedsted P., Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev 2018;19(2):319–24. DOI: 10.22034/APJCP.2018.19.2.319
13. Lemp J.M., De Neve J.W., Bussmann H. et al. Lifetime prevalence of cervical cancer screening in 55 low- and middle-income countries. JAMA 2020;324(15):1532–42. DOI: 10.1001/jama.2020.16244
14. Singh G.K., Azuine R.E., Siahpush M. Global inequalities in cervical cancer incidence and mortality are linked to deprivation, low socioeconomic status, and human development. Int J Mch Aids 2012;1(1):17–30. DOI: 10.21106/ijma.12
15. Broberg G., Wang J., Östberg A.L. et al. Socio-economic and demographic determinants affecting participation in the Swedish cervical screening program: a population-based case-control study. PLoS One 2018;13(1):e0190171. DOI: 10.1371/journal.pone.0190171
16. Endale H., Mulugeta T., Habte T. The socioeconomic impact of cervical cancer on patients in ethiopia: evidence from Tikur Anbessa Specialized Hospital. Cancer Manag Res 2022;14:1615–25. DOI: 10.2147/CMAR.S352389
17. Akinyemiju T., Ogunsina K., Sakhuja S. Life-course socioeconomic status and breast and cervical cancer screening: analysis of the WHO’s Study on Global Ageing and Adult Health (SAGE). BMJ Open 2016;6:012753. DOI: 10.1136/bmjopen-2016-012753
18. Xu T., Yang X., He X. The study on cervical cancer burden in 127 countries and its socioeconomic influence factors. J Epidemiol Glob Health 2023;13
19. Hull R., Mbele M., Makhafola T. et al. Cervical cancer in low and middleincome countries (review). Oncol Lett 2020;20:2058–74
20. Харибова Е.А., Набиева Ф.С. Морфометрическая характеристика шейки матки в норме, при фоновых и предраковых заболеваниях. Проблемы биологии и медицины.- 2023, №1 (142).- С. 328-329.
21. Вудман CB, Коллинз С.И., Янг Л.С. Естественное течение цервикальной ВПЧинфекции: нерешенные вопросы. Нат Преподобный Рак. 2007;7:11–22.
22. Роден RBS, Стерн PL. Возможности и проблемы вакцинации против вируса папилломы человека при раке. Нат Преподобный Рак. 2018;18:240–54.
23. Kaprin AD, Starinsky VV, Shakhzadova AO. The state of oncological care for the population of Russia in 2020. Moscow; 2021. (In Russ.).
24. Nie H, Bu F, Xu J, Li T, Huang J. 29 immune-related genes pairs signature predict the prognosis of cervical cancer patients. Sci Rep. 2020; 10: 14152. doi: 10.1038/s41598-020- 70500-5
25. Paik E, Lim MC, Kim MH, Kim YuH, Song ES, Seong JS, et al. Prognostic model for survival and recurrence in patients with earlystage cervical cancer: A Korean Gynecologic Oncology Group study (KGOG 1028). Cancer Res Treat. 2020; 52(1): 320-333. Doi: 10.4143/crt.2019.124
26. Global strategy to accelerate the elimination of cervical cancer as a public health problem. World Health Organization; 2020. Available to: https://www.who.int/publications/i/item/9789240 014107
27. Информационная записка ВОЗ: Комплексная профилактика рака шейки матки и борьба с ним – здоровое будущее для девочек и женщин. 2013. 16. [WHO guidance note: comprehensive cervical cancer prevention and control: a healthier future for girls and women. 2013. 16. (in Russian)].
28. Каюкова Е.В., Каюкова Т.В. Возможности онкомаркеров в выявлении рака шейки матки. Забайкальский медицинский журнал. 2015; 1: 38–44. [Kayukova E.V., Kayukova T.V. Possibilities of tumor markers in detecting cervical cancer. Zabaikal’skii meditsinskii zhurnal. 2015; 1: 38–44. (in Russian)].
29. Savostikova M.V., Sokolova V.K., Kudaibergenova A.G., Furminskaya E.Yu., Fedoseeva E.S. Cytomorphologist technical diagnosis of breast cancer. Oncogynecology. 2015;1:22–33. Savostikova MV, Sokolova VK, Kudaibergenova AG,
30. Выпуск новостей. АСТРО. 1 октября 2023 г. По состоянию на 10 октября 2023 г. https://www.astro.org/News-andPublications/News-and-Media-Center/NewsReleases/2023/Liquid-biopsies-can-rapidlydetect. -остаточные-болезни
31. Хан К., Цзоу Дж., Чжао З. и др. Клиническая валидация цДНК ВПЧ для раннего выявления остаточных заболеваний после химиолучевой терапии рака шейки матки. Представлено на: Ежегодном собрании Американского общества радиационной онкологии (ASTRO) 2023 г.; с 30 сентября по 4 октября 2023 г.; Сан-Диего, Калифорния. Аннотация 105
32. Zakharenko AA, Zaitsev DA, Belyaev MA, Trushin AA, Ten OA, Natkha AS. Possibilities of liquid biopsy in gastric cancer. Questions of oncology. 2016;62(4):379–385. (In Russ.)
33. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer discovery. 2016;6(5):479–491. PMID: 26969689. https://doi.org/10.1158/2159-8290.CD-15-1483
34. Arneth B. Update on the types and usage of liquid biopsies in the clinical setting: a systematic review. BMC Cancer. 2018 May 4; 18 (1): 527. doi: 10.1186/s12885-018-4433-3.
35. Tai Y.L., Chen K.C., Hsieh J.T., Shen T.L. Exosomes in cancer development and clinical applications. Cancer Sci. 2018 Aug; 109 (8): 2364–2374. doi: 36. 1111/cas.13697.
36. Neumann M.H.D., Bender S., Krahn Th., Schlange T. ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress. Comput Struct Biotechnol J. 2018 Jun 1; 16: 190–195. doi: 10.1016/j. csbj.2018.05.002. 37.
37. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. М., 2018. 236. [Kaprin A.D., Starinskii V.V., Petrova G.V. The state of oncological assistance to the population of Russia in 2017. Moscow, 2018. 236. (in Russian)]
38. Jia S., Zhang R., Li Z., Li J. Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomark- ers in colorectal cancer. Oncotarget. 2017 Apr 18; 8 (33): 55632–55645. doi: 10.18632/oncotarget.17184.
39. Quandt D., Zucht H.D., Amann A., Wulf-Goldenberg A., Borrebaeck C., Cannarile M., Lambrechts D., Oberacher H., Garrett J., Nayak T., Kazinski M., Massie C., Schwarzenbach H., Maio M., Prins R., Wendik B., Hockett R., Enderle D., Noerholm M., Hendriks H., Zwierzina H., Seliger B. Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget. 2017 Jul 18; 8 (29): 48507–48520. doi: 10.18632/oncotarget.17397.
40. Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35(3):347-376.
41. Swarup V., Rajeshwari M.R. Circulating (cell-free) nucleic acids are a promising noninvasive tool for early detection of a number of human diseases. Phoebe Lett. 2007;581(5):795- 799.
42. Sorenson G.D., Pribish D.M., Valone F.H., Memoli V.A., Bzik D.D., Yao S.L. Soluble normal and mutated DNA sequences of singlecopy genes in human blood. Biomarkers of cancer Epidemiology. 1994;3(1):67-71
43. Sakuma Y, Fujii K, Han J, Takahashi R-U. Recent advances in liquid biopsy based on circulating tumor DNA. Journal of clinical medicine. 2019;8(11):1957. PMID: 31766189. PMCID: PMC6912642. https://doi.org/10.3390/jcm8111957
44. Haber DA, Velculescu VE. Bloodbased analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer discovery. 2014;4(6):650–661. PMID: 24801577. PMCID: PMC4433544. https://doi.org/10.1158/2159- 8290.CD-13-1014
45. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–58. PMID: 23539594. PMCID: PMC3749880. https://doi.org/10.1126/ science.1235122
46. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15–26. PMID: 25584892. https://doi. org/10.1016/j.ccell.2014.12.001
47. Benoit L, Favoulet P, Collin F, et al. Prélèvements anatomopathologiques en cancérologie: règles de bonnes pratiques au bloc opératoire [Histological and cytopathological cancer specimens: good practice in operatingroom]. Ann Chir. 2003;128(9):637–641. https://doi.org/10.1016/j. anchir.2003.09.010
48. Cheng F., Su L., Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 2016 Jul 26; 7 (30): 48832–48841. doi: 10.18632/oncotarget.9453.
49. Campitelli M., Jeannot E., Peter M., Lappartient E., Saada S., de la Rochefordière A., Fourchotte V., Alran S., Petrow P., Cottu P., Pierga J.Y., Lantz O., Couturier J., Sastre-Garau X. Human papilloma- virus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One. 2012; 7 (8): e43393. doi: 10.1371/ journal.pone.0043393.
50. Guerrero-Preston R., Valle B.L., Jedlicka A., Turaga N., Folawiyo O., Pirini F., Lawson F., Vergura A., Noordhuis M., Dziedzic A., Pérez G., Renehan M., Guerrero-Diaz C., De Jesus Rodríguez E., Diaz-Montes T., Rodríguez Orengo J., Méndez K., Romaguera J., Trock B.J., Florea L., Sidransky D. Molecular triage of premalignant lesions in liquid-based cervical cytology and circulating cell-free DNA from urine, using a panel of methylated Human Papilloma Virus and host genes. Cancer Prev Res (Phila). 2016 Dec; 9 (12): 915–924. doi: 10.1158/1940- 6207.CAPR-16-0138.
51. Mendez K., Romaguera J., Ortiz A., López M., Steinau M., UngerE. Urine-based human papillomavirus DNA testing as a screening tool for cervical cancer in high-risk women. Int J Gynaecol Obstet. 2014 Feb; 124 (2): 151–155. doi: 10.1016/j.ijgo.2013.07.036.
52. Ducancelle A., Legrand M.C., Pivert A., Veillon P., Le GuillouGuillemette H., De Brux M.A., Beby-Defaux A., Agius G., Hantz S., Alain S., Catala L., Descamps P., Postec E., Caly H., Charles-Pétillon F., Labrousse F., Lunel F., Payan C. Interest of Human Papillomavirus DNA quantification and genotyping in paired cervical and urine samples to detect cervical lesions. Arch Gynecol Obstet. 2014; 290 (2): 299– 308. doi: 10.1007/s00404-014-3191-y.
53. Maged A.M., Saad H., Salah E., Meshaal H., AbdElbar M., Omran E., Eldaly A. Urine test for HPV genotypes as a predictor of precan- cerous cervical lesions and for cervical cancer screening. Int J Gynaecol Obstet. 2018 Jun; 141 (3): 332–336. doi: 10.1002/ijgo.12453.
54. Chung T.K.H., Cheung T.H., Yim S.F., Yu M.Y., Chiu R.W.K., Lo K.W.K., Lee I.P.C., Wong R.R.Y., Lau K.K.M., Wang V.W., Worley M.J.Jr., Elias K.M., Fiascone S.J., Smith D.I., Berkowitz R.S., Wong Y.F. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. Gynecol Oncol. 2017 Aug; 146 (2): 334–339. doi: 10.1016/j.ygyno.2017.05.038.
55. Haidary M, Bauer M, Uls P, Heather E, Pe truE, Gesch C, etc. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast cancer Res. 2014;16:421. doi: 10.1186/s13058-014-0421-y.
56. Garcia-Murillas I., Chopra N., Comino-M ndez I. et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019.
57. O’Leary B., Hrebien S., Beaney M. et al. Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clin Chem. 2019; 65(11):1405-1413.
58. Coombes R.C., Page K., Salari R. et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res. 2019; 25(14):4255-4263.
59. Parsons H.A., Rhoades J., Reed S.C. et al. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020.
60. Tie J., Cohen J.D., Wang Y. et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. 2019;8(4):663-671.
61. Reinert T., Henriksen T.V., Christensen E. et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019.
62. Ou S.I., Nagasaka M., Zhu V.W. Liquid Biopsy to Identify Actionable Genomic Alterations. Am Soc Clin Oncol Educ Book. 2018; 38: 978-997.
63. Galot R., van Marcke C., Helaers R. et al. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2020;104: 104631.
64. Amant F., Verheke M., Wlodarska I. et al. The asymptomatic detection of cancer in pregnant women during noninvasive prenatal testing. JAMA Oncol. 2015;1(6):814-819.
65. Fallen J., Sausen M., Adleff V. et al. Direct detection of cancer in the early stages using circulating tumor DNA. Scientific translation of Honey. 2017;9(403):eaan2415.
66. Agassi R., Zeiger D., Shaked G., et al. Measurement of circulating extracellular DNA levels using a simple fluorescent test in breast cancer patients. Am J. The wedge is Patol. 2015;143(1):18-24.
67. Rohanizadegan M. Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. Cancer is coming. 2018;228-229:159-168.
68. Zanetti-Dellenbach R.A., Schmid S., White E. et al. Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Int J Biol Markers. 2007;22(2):95-99